For decades, quantum computing research largely happened in university laboratories, where the field’s tremendous theoretical potential contrasted with the reality of slow, incremental progress. Today, though, startups and established tech companies are helping to drive advances in the field, bringing quantum computing into the mainstream.
Toronto fintech digit has kept a low profile since rolling out its product a year ago.
The company, pronounced “digit,” provides an all-in-one software solution giving financial advisers more granular data, which is being used by some of Canada’s wealthiest family offices and investment firms.
Deep Genomics, an artificial intelligence-powered drug discovery start-up co-founded by the University of Toronto’s Brendan Frey, recently raised $40 million in Series B funding, Betakit reports.
The latest round, led by Future Ventures and including investments from Amplitude Ventures, Khosla Ventures, Magnetic Ventures and True Ventures, brings the startup’s total funding to date to $61 million.
TORONTO — Deep Genomics, the leading artificial intelligence (AI) therapeutics company, announced today the closing of its Series B round with $40 million in new investment. The proceeds from this financing will be used to develop new treatments for rare genetic diseases, and to expand the company’s proprietary AI discovery platform to support the discovery and development of novel therapies for more common disorders